ADMET analysis predicted favorable pharmacokinetic and safety profiles. Collectively, these findings identified compound 7e as a promising dual VEGFR-2/CDK6 inhibitor with potent and selective anticancer activity, warranting further preclinical investigation.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed as antidiabetic agents, have emerged as candidate disease-modifying therapies for Parkinson’s disease (PD) and Alzheimer’s disease (AD), reflecting the widespread expression of GLP-1 receptors across neurons, glia, and the cerebral vasculature. This narrative review synthesizes mechanistic, clinical trial, and biomarker evidence for GLP-1 RAs in PD and AD, based on a literature search of PubMed, Embase, Scopus, and Web of Science, with ClinicalTrials.gov searched separately for trial protocols and results, through May 2026. Preclinical data implicate GLP-1 receptor agonism in anti-neuroinflammatory signaling, mitochondrial preservation, autophagy and proteostasis enhancement, anti-apoptotic effects, synaptic plasticity, cerebrovascular protection, and glymphatic clearance. Clinical evidence in PD is mixed and agent- and formulation-dependent: the phase II Exenatide-PD trial reported a motor benefit that persisted after washout (∼3.5-point between-group difference in MDS-UPDRS Part III), and the phase II LIXIPARK trial (lixisenatide) reported a significant 3.08-point between-group difference (95% CI 0.86–5.30; p = 0.007) favoring lixisenatide, whereas the larger, longer phase III Exenatide-PD3 trial, using an extended-release weekly formulation, found no significant effect on the same endpoint (adjusted coefficient 0.92; 95% CI −1.56 to 3.39; p = 0.47); oral semaglutide is under investigation in the ongoing phase II MOST-ABLE trial. In AD, the phase IIb liraglutide (ELAD) trial did not achieve statistical benefit on either its primary imaging endpoint (cerebral glucose metabolic rate; p = 0.14) or on most secondary cognitive measures, and the phase III semaglutide trials EVOKE and EVOKE+ did not meet their primary CDR-SB endpoint (estimated difference −0.08, 95% CI −0.35 to 0.20, p = 0.57 in EVOKE; 0.10, 95% CI −0.17 to 0.38, p = 0.46 in EVOKE+), despite biomarker signals including reductions in cerebrospinal fluid tau species and inflammatory markers. Comparative pharmacology reveals substantial heterogeneity in central nervous system penetration, receptor engagement, and systemic bioavailability across exenatide, liraglutide, semaglutide, and the imbalanced GLP-1/GIP co-agonist tirzepatide, complicating cross-agent extrapolation. Persistent challenges include separating direct neuroprotection from indirect metabolic and cardiovascular benefit, limited characterization of brain drug exposure, trial durations that may be short relative to the expected latency of a disease-modifying effect, and the absence of validated response biomarkers. We conclude that although the mechanistic and epidemiological rationale for GLP-1 RAs in neurodegeneration remains biologically plausible, current trial evidence does not yet support their use outside clinical trials, irrespective of comorbid diabetes status; future studies should prioritize earlier intervention, biomarker-guided patient selection, adequately powered subgroup analyses, and brain-penetrant formulations.
BACKGROUND: Unintentional poisoning is a preventable cause of injury-related morbidity and mortality, yet global patterns, trends, and inequalities remain incompletely characterised. Within the Global Burden of Disease (GBD) framework, unintentional poisoning includes poisoning by carbon monoxide and poisoning by other means, a category largely informed by pesticide poisoning codes plus some indirect capture of other poisoning as part of the GBD re-distribution process. Poisonings by pharmaceuticals and illicit substances are not captured in the GBD definition of poisoning. We aimed to quantify this GBD-defined burden and assess regional variation, sociodemographic gradients, and case fatality between 1990 and 2023. METHODS: We analysed GBD 2023 estimates for 204 countries and territories, modelling deaths, incidence, and disability-adjusted life-years (DALYs) using standard GBD cause-of-death and non-fatal estimation methods with 95% uncertainty intervals. We stratified results by age, sex, region, and Socio-demographic Index (SDI), and derived case fatality from modelled deaths and incidence. FINDINGS: In 2023, unintentional poisoning from carbon monoxide and other means caused 2·54 million incident poisonings, 69 805 deaths, and 3·68 million DALYs globally, with age-standardised DALY rates declining by 47·5% since 1990. Carbon monoxide accounted for 641 932 poisonings, 30 890 deaths and 1·34 million DALYs, with the highest burdens in central and eastern Europe and central Asia. Most regions showed substantial long-term declines, and the global age-standardised DALY rate for carbon monoxide poisoning declined by 58·2% since 1990. Poisoning by other means caused 1·90 million incident cases, 38 914 deaths, and 2·34 million DALYs, with the greatest burden in sub-Saharan Africa. Most regions showed declining age-standardised DALY rates for poisoning by other means; however, there was no clear change (with the 95% uncertainty interval including zero) in the global estimate, driven by wide uncertainty intervals in several regions (including sub-Saharan Africa). Mortality and DALYs were inversely associated with SDI, and derived case fatality was highest in low-SDI regions. INTERPRETATION: Global reductions in GBD-defined unintentional poisoning by carbon monoxide and other means are consistent with decades of regulatory and environmental interventions. These include bans of highly toxic pesticides, improved heating and ventilation systems, emissions controls, and adoption of carbon monoxide alarms. Stark inequalities persist in some regions and in low-SDI settings. Compared with previous GBD publications, this study provides a detailed global assessment of unintentional poisoning by carbon monoxide and other means up to 2023, integrating incidence, DALYs, and comparative case fatality across regions. FUNDING: Gates Foundation and the Australian National Health and Medical Research Council.
accidental poisoningpoisoning mortalityinjury burdenglobal burden of disease
Frontiers in Pharmacology · مجلد 17 · 1871321-1871321
Background Although microRNAs have been investigated, the reno-protective role of microRNA-205 (miR-205) in cyclophosphamide (CPA)-induced nephrotoxicity has not yet been explored. Therefore, this study evaluated the influence of buspirone on miR-205 and its downstream target EGLN2, focusing on oxidative and ER stress as key drivers of renal injury. This represents a significant gap in nephrotoxicology and epigenetic Toxicology research. Methods Animals were randomly allocated among four groups (n = 8), including the normal control group and the CPA group that received one intraperitoneal injection of CPA at 200 mg/kg on day 7. Buspirone at 5 or 10 mg/kg per day was administered by oral gavage for ten consecutive days, whereas CPA injected on the seventh day. At experimental completion, blood samples and renal tissues were subjected to analysis using biochemical, histopathological, immunohistochemical, Western blotting, and qRT-PCR techniques. Results CPA induced marked renal dysfunction, reflected by elevated SCr, BUN, NGAL, and KIM-1, with evident histopathological damage. This was accompanied by miR-205 suppression, EGLN2 upregulation, impaired Nrf2 signaling, increased PC levels, and stimulation of PERK/eIF2α/ATF4/CHOP-linked ER stress signaling ( p < 0.01). Concurrently, activation of JNK1, Fos, and NF-κB increased inflammatory cytokines, and initiated caspase-dependent apoptotic signaling ( p < 0.01). Buspirone pretreatment mitigated these alterations, accompanied by increased miR-205 expression, reduced EGLN2 expression, enhanced Nrf2-associated antioxidant defenses, and attenuation of ER stress, inflammation, and apoptosis, thereby preserving renal function and tissue integrity. Conclusion These findings highlight the preventive renoprotective potential of buspirone against CPA-induced nephrotoxicity and underscore the relevance of miR-205/EGLN2 signaling in renal stress responses. Future toxicokinetic and toxicodynamic studies should evaluate buspirone’s safety in tumor treatment.
Asian Pacific Journal of Cancer Prevention · مجلد 27 (8) · 2853-2860
BACKGROUND: Retinoblastoma (Rb) represents the most frequent primary intraocular cancer in the pediatric population; yet comprehensive national data are limited in Saudi Arabia due to incomplete cancer registry coverage and underreporting. The present study systematically investigates the incidence, distribution, and trends of retinoblastoma across Saudi Arabia over two decades, utilizing robust data from the Saudi National Cancer Registry (SCR), a nationwide surveillance system overseen by the Ministry of Health. METHODS: This retrospective population-based analysis included all children diagnosed with Rb in Saudi Arabia between January 1, 2000, and December 31, 2019. The study examined incidence rates and temporal patterns by age, regional location, and tumor histology. RESULTS: Out of 542 documented cases (258 females, 284 males), the age-standardized incidence rate (ASIR) for children aged 0-4 years demonstrated an initial increase, peaking at 1.26 per 100,000 in 2003, followed by a gradual decline to 0.93 per 100,000 by 2019. Higher incidence rates were detected in major urban centers, especially Riyadh and Makkah, likely reflecting demographic density, enhanced diagnostic practices, and more accessible specialized care. Most tumors were either undifferentiated (Grade IV) or not otherwise specified (NOS, 63%), while diffuse retinoblastoma was rare (2%). Diagnosis was predominantly confirmed by histopathological evaluation (88.3%). CONCLUSION: This study offers the most comprehensive picture to date of retinoblastoma incidence and patterns in Saudi Arabia. The observed rising incidence, together with regional disparities, emphasizes the need for more refined cancer surveillance, equitable resource allocation, and accelerated early detection strategies, particularly in underserved areas. These findings provide essential baseline metrics to inform national cancer control policies and optimize equitable resource distribution.
retinoblastomapediatric cancer incidenceSaudi Arabiaage-standardized incidence rate
Kho-Kho is a high-intensity traditional sport characterized by rapid directional changes, relay-based movement patterns, and sustained postural demands, requiring well-developed agility, balance, and functional movement capacity. This study examined pre-post changes in functional movement, postural stability, and agility during a short-term camp-based functional strength and balance training period in male and female national-level Kho-Kho players. This single-arm, pre-post interventional trial included 60 national-level Kho-Kho players (30 males, 30 females) who participated in a two-week intensive functional strength and balance training program conducted during a training camp. No concurrent control group was included. Pre- and post-training assessments included the Functional Movement Screen (FMS), static balance under open- and closed-eye conditions, dynamic balance on both and single limbs, and agility performance using SEMO and Illinois tests. Linear sprint speed was assessed using a 40 m run test. Sex-based differences were examined using independent t tests, and two-factor ANOVA was used to examine differences according to time point, sex, and their interaction for selected performance outcomes. Significant pre-post changes were observed in FMS composite scores for both sexes ( p ≤ 0.001, η 2 p = 0.66). Static balance scores changed favorably under both visual conditions (open eyes: p ≤ 0.001, η 2 p = 0.82; closed eyes: p ≤ 0.001, η 2 p = 0.76). Dynamic balance showed significant time-related changes in overall analysis for both-feet and single-limb conditions ( p ≤ 0.001, η 2 p = 0.25 and 0.35, respectively), although within-sex analysis showed that the female single-foot condition did not change significantly. Agility test times showed significant pre-post reductions in SEMO and Illinois tests ( p ≤ 0.001, η 2 p = 0.66 and 0.68), whereas the 40 m run test showed no significant changes ( p = 0.28). Significant overall differences between male and female players were identified for dynamic balance on both feet ( p = 0.007, η 2 p = 0.12) and agility outcomes (SEMO: p ≤ 0.001, η 2 p = 0.37; Illinois: p ≤ 0.001, η 2 p = 0.38). During the short-term structured camp-based functional strength and balance training period, favorable pre-post changes were observed in functional movement, postural stability, and agility among national-level Kho-Kho players. Because of the single-arm pre-post design, the absence of a concurrent control group, and possible agility-test familiarization effects, the findings describe changes observed over time and do not establish that the training program caused the observed changes. Controlled studies are required to determine the independent contribution of the training program. Trial registration : ClinicalTrials.gov, NCT06602895; retrospectively registered on 17 September 2024, after participant enrolment and commencement of the study.
Diabetic neuropathy (DN) is a multifactorial complication of diabetes mellitus driven by chronic hyperglycemia, insulin resistance, and disturbed metabolic homeostasis, leading to progressive injury of both the peripheral and central nervous systems. This study investigated whether L-serine supplementation could attenuate DN through dose-dependent metabolic and neuroprotective mechanisms in a high-fat diet (HFD) plus streptozotocin (STZ)-induced diabetic rat model. Male Wistar rats (n = 8 per group) were allocated to five groups: normal control (NC), diabetic control (DC), pioglitazone (PIO; 1.5 mg/kg/day), low-dose L-serine (S1; 200 mg/kg/day), and high-dose L-serine (S2; 400 mg/kg/day). After 60 days of oral gavage, behavioural testing, glucose and insulin profiling, HOMA-IR calculation, brain histopathology, nerve growth factor (NGF) immunohistochemistry, and LC–MS/MS-based proteomic analysis of cerebral tissue were performed. Diabetic rats exhibited marked hyperglycaemia (355.33 ± 4.72 mg/dL), hyperinsulinaemia, severe insulin resistance (HOMA-IR 16.8 ± 3.2; a 14-fold increase), impaired thermal nociception, motor dysfunction, and pronounced neuronal degeneration. L-serine supplementation significantly improved metabolic status: S1 reduced HOMA-IR by 77.4% and S2 by 87.5% relative to diabetic controls (p < 0.001). High-dose L-serine produced greater improvements in thermal sensitivity, motor coordination (rotarod latency 26.67 ± 1.52 s vs. 16.1 ± 0.85 s in DC; p < 0.05), and NGF expression (8.6-fold increase vs. DC). Histopathology confirmed attenuation of neuronal injury and gliosis in both treatment groups. Exploratory, group-level proteomic profiling identified dose-specific molecular signatures: S1 was predominantly associated with carbohydrate, lipid, and biosynthetic pathways, whereas S2 was associated with synaptic, neurotransmission-related, and proteostasis pathways. Within the constraints of an exploratory design—group-level pooled proteomics, analysis of cerebral rather than peripheral-nerve tissue, and only two doses—these findings indicate that L-serine attenuates the metabolic and behavioural features of experimental diabetic neuropathy and generates the testable hypothesis of dose-dependent neuro-metabolic remodelling. The proteomic signatures are hypothesis-generating and require orthogonal validation before any mechanistic or translational inference can be drawn.
Progress in Disaster Science · مجلد 31 · 100630-100630
Background Disaster preparedness in long-term care (LTC) hospitals is critical, as these facilities house vulnerable populations with complex care needs. Objectives To assess disaster management knowledge and preparedness among nurses in an LTC hospital in Riyadh, Saudi Arabia, and to examine the influence of sociodemographic and professional characteristics. Methods A cross-sectional descriptive study of 116 registered nurses in a 128-bed LTC hospital in Riyadh. Data were collected via self-administered paper-based questionnaires during December 2025 using the Arabic Disaster Preparedness Evaluation Tool (DPET). Data were analyzed using IBM SPSS Statistics version 25. Results 85.3% of nurses demonstrated high preparedness in Knowledge (mean = 4.86, SD = 0.65) and Preparedness/Skills (mean = 4.89, SD = 0.70); 89.7% scored high in Post-Disaster Management (mean = 4.91, SD = 0.64). Prior training significantly improved knowledge ( p = 0.014, r = −0.23) and preparedness ( p = 0.024, r = −0.21). Experience was associated with post-disaster management ( p = 0.013, η 2 = 0.070). Conclusions High disaster preparedness was demonstrated. Mandatory LTC-specific training programs are recommended.
disaster preparednessdisaster managementnurseslong-term care hospitals
Journal of Biomolecular Structure and Dynamics · مجلد 44 (15) · 6664-6676
Dipeptidyl peptidase 4 (DPP4/CD26) is a clinically relevant serine protease involved in metabolic, immunological and viral processes. Although several crystal structures of DPP4-ligand complexes have been reported, the dynamic features that distinguish substrates from inhibitors remain less understood. In this study, 250 ns all-atom molecular dynamics simulations were performed for four structurally distinct ligand-bound states, a synthetic construct, a Neuropeptide Y (NPY) fragment, Diprotin A and an HIV-1 TAT peptide, to examine how ligand identity affects the conformational behavior of DPP4. All complexes maintained the global α/β-hydrolase and β-propeller architecture, with secondary-structure content remaining stable throughout the simulations. Ligand-dependent differences were mainly observed in the flexible loop regions near the catalytic cavity. The inhibitory ligands (Diprotin A and TAT) promoted reduced mobility and lower backbone RMSD values (1.5-2.0 Å), whereas the substrate and the synthetic construct allowed greater local flexibility (2.0-2.5 Å). Contact analyses showed a conserved anchoring network involving Glu205, Glu206 and Tyr662 across all systems, along with ligand-specific peripheral interactions, including Trp659, Tyr752 and Phe357, that influence the binding modes. These observations reveal a relationship among structure-dynamics-function, in which DPP4 maintains a stable interaction and modulates loop movements, including peripheral contacts, to differentiate substrates from inhibitors. The dynamic behavior of the enzyme offers mechanistic insights that allow for specific ligand recognition, which could support the design and development of new DPP4 modulators.